Gastric cancer(GC)represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every year.In the last decade,the de...Gastric cancer(GC)represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every year.In the last decade,the development of targeted therapies and the optimization of already available chemotherapeutic drugs has expanded the available treatment options for advanced GC and granted better survival expectations to the patients.At the same time,global efforts have been undertaken to investigate in detail the genomic and epigenomic heterogeneity of this disease,resulting in the identification of new specific and sensitive predictive and prognostic biomarkers and in innovative molecular classifications based on gene expression profiling.Nonetheless,several randomized studies aimed at exploring new innovative agents,such as immune checkpoint inhibitors,failed to demonstrate clinically meaningful survival advantages.Therefore,it is essential to further improve the molecular characterization of GC subgroups in order to provide researchers and medical oncologists with new tools for patients’selection and stratification in future clinical development programs and subsequent trials.The aim of the present manuscript is to provide a global overview of the recent molecular classifications from The Cancer Genome Atlas and the Asian Cancer Research Group and to present key promising developments in the field of immunotherapy and targeted therapies in metastatic GC.展开更多
In the last few years we have witnessed a vast expansion of our knowledge regarding the molecular and genetic profile of gastric cancer.The molecular subtypes described have shed light on the pathogenesis of the disea...In the last few years we have witnessed a vast expansion of our knowledge regarding the molecular and genetic profile of gastric cancer.The molecular subtypes described have shed light on the pathogenesis of the disease,thus prompting the development of new therapeutic strategies and favoring a more individualized approach for treatment.Most of the clinical trials for so called targeted therapies could be considered,at best,partially successful.In addition,checkpoint inhibitors ha-ve recently been added to our armamentarium in later stages of the disease,and combinations with chemotherapy and targeted agents are currently under development.In view of the rapid advances of molecular oncology,a new challenge for the clinical oncologist arises: The appropriate patient selection for each new therapy,which can be made possible only through the implementation of predictive biomarkers in our therapy decision making.展开更多
文摘Gastric cancer(GC)represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every year.In the last decade,the development of targeted therapies and the optimization of already available chemotherapeutic drugs has expanded the available treatment options for advanced GC and granted better survival expectations to the patients.At the same time,global efforts have been undertaken to investigate in detail the genomic and epigenomic heterogeneity of this disease,resulting in the identification of new specific and sensitive predictive and prognostic biomarkers and in innovative molecular classifications based on gene expression profiling.Nonetheless,several randomized studies aimed at exploring new innovative agents,such as immune checkpoint inhibitors,failed to demonstrate clinically meaningful survival advantages.Therefore,it is essential to further improve the molecular characterization of GC subgroups in order to provide researchers and medical oncologists with new tools for patients’selection and stratification in future clinical development programs and subsequent trials.The aim of the present manuscript is to provide a global overview of the recent molecular classifications from The Cancer Genome Atlas and the Asian Cancer Research Group and to present key promising developments in the field of immunotherapy and targeted therapies in metastatic GC.
文摘In the last few years we have witnessed a vast expansion of our knowledge regarding the molecular and genetic profile of gastric cancer.The molecular subtypes described have shed light on the pathogenesis of the disease,thus prompting the development of new therapeutic strategies and favoring a more individualized approach for treatment.Most of the clinical trials for so called targeted therapies could be considered,at best,partially successful.In addition,checkpoint inhibitors ha-ve recently been added to our armamentarium in later stages of the disease,and combinations with chemotherapy and targeted agents are currently under development.In view of the rapid advances of molecular oncology,a new challenge for the clinical oncologist arises: The appropriate patient selection for each new therapy,which can be made possible only through the implementation of predictive biomarkers in our therapy decision making.
